摘要
目的探讨盐酸帕罗西汀片治疗抑郁症发作情绪障碍对P物质(SP)、神经肽Y(NPY)、5-羟色胺(5-HT)、去甲肾上腺素(NE)水平的影响。方法选取2019年1月至2020年1月本院收治的抑郁症发作情绪障碍患者95例,给予患者盐酸帕罗西汀片治疗。治疗前、治疗4、6、8周时,采用汉密尔顿抑郁量表(HAMD-24)和汉密尔顿焦虑量表(HAMA)评估患者焦虑、抑郁情绪,采用情感障碍自评量表评估患者情绪障碍;采用酶联免疫吸附法(ELISA)测定不同时间患者脑脊液内P物质、神经肽Y、5-羟色胺、去甲肾上腺素(NE)及5-羟吲哚乙酸(5-HIAA)水平。结果治疗4、6、8周时,患者HAMD、HAMA、情感障碍评分均低于治疗前,差异有统计学意义(P<0.05);治疗4、6、8周时,患者NPY、5-HT、5-HIAA、NE均高于治疗前,SP低于治疗前,差异有统计学意义(P<0.05)。结论盐酸罗帕西汀片治疗抑郁发作时情绪障碍,能显著抑制抑郁、焦虑及情绪障碍症状,改善患者多种神经递质功能,效果显著,值得临床推广。
Objective To investigate the effect of paroxetine hydrochloride tablets on the level of P substance(SP),neuropeptide Y(NPY),5-hydroxyhydroxyl(5-HT)and norepinephrine(NE)in the treatment of depressive episode mood disorder.Methods The patients were treated with paroxetine hydrochloride tablets.Before treatment,4,6 and 8 weeks after treatment,Hamilton Depression Scale(HAMD-24)and Hamilton Anxiety Scale(HAMA)were used to evaluate the anxiety and depression of patients.P substances,neuropeptide Y,5-hydroxyhydroxyl in cerebrospinal fluid of patients at different times were determined by enzyme-linked immunosorbent assay(ELISA)levels of tryptamine,classical neurotransmitter norepinephrine,and 5-hydroxyindoleacetic acid(5-HIAA).Results At 4,6 and 8 weeks of treatment,the scores of HAMD,HAMA,affective disorders were significantly lower than those before treatment(P<0.05).At 4,6 and 8 weeks of treatment,the NPY,5-HT,5-HIAA,NE of patients were higher than before treatment,the SP was lower than before treatment,and the difference was statistically significant(P<0.05).Conclusion Ropazitine hydrochloride tablets can significantly inhibit mood disorder during depression make depression,anxiety and mood disorder symptoms,improve the function of various neurotransmitters in patients,the effect is remarkable,worthy of promotion.
作者
李吉军
陈丰博
张冬梅
LI Jijun;CHEN Fengbo;ZHANG Dongmei(Third Department of Psychiatry,Dandong Third Hospital,Dandong,Liaoning,118000,China)
出处
《当代医学》
2021年第33期28-30,共3页
Contemporary Medicine
关键词
情绪障碍
盐酸帕罗西汀片
P物质
神经肽Y
5-羟色胺
去甲肾上腺素
临床效果
Mood disorder
Paroxetine hydrochloride tablets
P substances
Neuropeptide Y
5-hydroxytryptamine
Norepinephrine
Clinical effect